|
1.
|
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. MedStar authors:
Year: 2014
Citation: - Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 9(1):121-5, 2014 Jan.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase I
- Clinical Trial, Phase II
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Adams JW, Berger MS, Chiappori A, Edelman MJ, Haura EB, Malik S, Northfelt DW, Rosen P, Van Echo DA, Williams C
|
|
2.
|
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. MedStar authors:
Year: 2019
Citation: - Journal of Clinical Oncology. 37(7):537-546, 2019 03 01.
Institution: - Medstar Franklin Square Medical Center
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riccio A, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Vandormael K, Yang J
|